In 2013, the Nobel Prize in Physiology or Medicine was awarded to three scientists in recognition of their outstanding contributions in the field of intercellular vesicle transport regulation mechanisms, which pushed the enthusiasm of exosomes research to a climax.

At present, it is generally believed that unlike common microvesicles, which are directly generated by cell budding and detachment, the formation of exosomes begins with cell invagination to form early endosomes, followed by the regulation of endosomal transport complexes and some related proteins, early endosomal budding to form MVBs composed of multiple intraluminal vesicles, which finally fuse with the cell membrane to the external secretory cavity vesicles under the regulation of RAB enzymes in the GTPase family, that is, exosomes.

Function of exosomes In recent years, more and more studies have shown that exosomes play an extremely important role in tumor diagnosis, migration and growth, tissue damage repair, immune antigen presentation and neurodegenerative diseases.

immobilized known tumor surface markers on the chip and detected cell and plasma exosome markers by antibody chip, respectively, and about 40% of cancer cell surface markers were reflected on the vesicle surface, indicating that antibody chip detection of exosome surface proteins is expected to be applied in tumor diagnosis.

It has been found that the cell surface proteoglycan phosphatidylinositol glycan-1 is abundant in the blood exosomes of individuals with pancreatic cancer.

With the study of functional proteins, mRNAs and miRNAs contained in exosomes, the role of exosomes in signal transduction in vivo has also been gradually recognized, and they play an extremely important role in the diagnosis and treatment of cardiovascular diseases, nervous system diseases and tumors.

Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.

Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.

Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.

In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8057 Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.

Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.SegmentationThe global theranostics market has been segmented into the therapeutic area, technology, end user, and region.By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others.

The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others.

Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.

Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.

Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.

In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8057 Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.

Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.SegmentationThe global theranostics market has been segmented into the therapeutic area, technology, end user, and region.By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others.

The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others.

Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.

Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.

Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.

In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8057 Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.

Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.SegmentationThe global theranostics market has been segmented into the therapeutic area, technology, end user, and region.By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others.

The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others.

Theranostics Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.

Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.

Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.

In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.

Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.Theranostics Market SegmentationThe global theranostics market has been segmented into the therapeutic area, technology, end user, and region.By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others.

The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others.

Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.

Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.

Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.

In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8057 Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.

Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.SegmentationThe global theranostics market has been segmented into the therapeutic area, technology, end user, and region.By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others.

The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others.

Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.

Get Free Sample@ https://www.marketresearchfuture.com/sample_request/8057  Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.

Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.

In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.

SegmentationThe global theranostics market has been segmented into the therapeutic area, technology, end user, and region.By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others.

The sequencing segment is likely to register comparatively higher CAGR over the forecast period due to the increasing number of proof-of-concept case studies and research related to sequencing, particularly next-generation sequencing (NGS) technology.Based on end user, the market has been classified into hospitals and clinics, diagnostic laboratories, and others.Browse Full Report Details @ https://www.marketresearchfuture.com/reports/theranostics-market-8057 Key PlayersFew of the prominent players in the global theranostics market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Focus Diagnostics, Abbott Laboratories, Illumina, Inc., Agilent Technologies, Inc., QIAGEN, Myriad Genetics, Inc., Foundation Medicine, Inc., and AmeriPath, Inc.

 Key Playersof the prominent players in the global theranostics market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Focus Diagnostics, Abbott Laboratories, Illumina, Inc., Agilent Technologies, Inc., QIAGEN, Myriad Genetics, Inc., Foundation Medicine, Inc., and AmeriPath, Inc. Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.

Get Free Sample@ https://www.marketresearchfuture.com/sample_request/8057 Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.

Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.

In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.

The sequencing segment is likely to register comparatively higher CAGR over the forecast period due to the increasing number of proof-of-concept case studies and research related to sequencing, particularly next-generation sequencing (NGS) technology.Based on end user, the market has been classified into hospitals and clinics, diagnostic laboratories, and others.Browse Full Report Details @ https://www.marketresearchfuture.com/reports/theranostics-market-8057 Regional AnalysisThe global theranostics market has been categorized on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

On a regional basis, the Americas would command the market throughout the forecast period attributed to the domicile of major market participants, increasing research and development activities, and growing adoption of theranostics in the US and Canada.